Overview

Beta-hCG + Erythropoietin in Acute Stroke

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety of Beta-hCG + Erythropoietin in patients with acute ischemic stroke.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, Irvine
Collaborators:
Hoag Memorial Hospital Presbyterian
Stem Cell Therapeutics Corp.
Treatments:
Epoetin Alfa
Mitogens